Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Total Non-current Assets
All assets not expected to be converted to cash within one year.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 43.3% from a year ago
Total non-current assets stood at $861K at the end of Q1 FY2026, up 43.3% from a year earlier and up 394.8% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Total non-current assets amounted to 1.3% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +43.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 174K USD
- Year-over-year change
- -75.8%
- 4-year CAGR
- -15.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 174K | -75.8% |
| FY2024 | 2024-12-31 | 720K | -9.1% |
| FY2023 | 2023-12-31 | 792K | +355.2% |
| FY2022 | 2022-12-31 | 174K | -47.7% |
| FY2021 | 2021-12-31 | 333K | — |
Total Non-current Assets vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +43.3% is the highest of 10, against a peer median of -65.6%.
- Total non-current assets amounts to 1.3% of total assets for UNCY, versus a peer median of 3.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $291.13M USD | -5.8% | +152.1% | 89.8% |
| Mar 2026 | $48.35M USD | -49.6% | -2.8% | 26.9% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $8.61M USD | -65.6% | -42.6% | 8.0% |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$4.2M CAD | -83.0% | -22.9% | 18.1% |
| Mar 2026 | $3.26M USD | -70.6% | — | 3.1% | |
| Mar 2026 | $983K USD | -36.2% | -14.4% | 0.5% | |
| Mar 2026 | $861K USD | +43.3% | +0.0% | 1.3% | |
| Mar 2026 | $782K USD | -89.0% | -61.4% | 0.8% | |
| Mar 2026 | $67K USD | -99.4% | -64.3% | 0.1% | |
| Mar 2026 | $19.5K USD | -11.3% | -17.6% | 0.0% | |
| Peer median (excluding UNCY) | — | -65.6% | -20.3% | 3.1% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.